Overall and disease-specific survival of sinonasal adenoid cystic carcinoma: a systematic review and meta-analysis

Rhinology. 2023 Dec 1;61(6):508-518. doi: 10.4193/Rhin23.204.


This meta-analysis aims to investigate the outcome of sinonasal adenoid cystic carcinoma (snAdCC). We followed PRISMA guidelines and included studies reporting 5-year overall survival (OS) rates for snAdCC. Eligible studies were identified through a literature search and assessed using JBI critical appraisal checklist. A total of 17 studies were included comprising 2259 patients (mean age: 58.1 years, 52.7% female, 47.3% male). The meta-analysis demonstrated that the 5-year OS, 10-year OS, and 5-year disease-free survival (DFS) were 68%, 40%, and 47.2%, respectively. Descriptive statistics on study level showed high rates of locally advanced tumor stages at diagnosis: 23% cT3, 53% cT4, 3.4% N+, and 4.2% M+. 29.7% of the tumors were in the nasal cavity, 67.6% in the paranasal sinuses. The maxillary, ethmoid, sphenoid, and frontal sinus were affected in 50.9%, 7.2%, 4%, and 0.5%, of cases. A combination of surgery and radiotherapy was used in 45.4% of the patients and 19.3% of patients received surgery only. In conclusion, these findings emphasize the significance of thorough surveillance for individuals with snAdCC to identify any potential recurrence or progression of the disease.

Publication types

  • Meta-Analysis
  • Systematic Review

MeSH terms

  • Carcinoma, Adenoid Cystic* / pathology
  • Carcinoma, Adenoid Cystic* / radiotherapy
  • Female
  • Frontal Sinus* / pathology
  • Humans
  • Male
  • Middle Aged
  • Nose Neoplasms* / pathology
  • Paranasal Sinus Neoplasms* / pathology
  • Paranasal Sinus Neoplasms* / therapy
  • Retrospective Studies